BChE-IN-13 (Compound 17c) is an orally active, potent, and selective inhibitor of Butyrylcholinesterase (BChE). It exhibits IC50 values of 0.22 μM and 0.016 μM for eqBChE and hBChE, respectively. BChE-IN-13 demonstrates the capability to enhance memory and cognitive impairments, making it valuable for Alzheimer's disease (AD) research [1].

BChE-IN-13 (5-100 μM; 24 h) shows weak toxicity to SH-SY5Y, PC-12 and HT-22, and shows high mortality to BV2 cells [1]. BChE-IN-13 shows excellent blood brain barrier permeation using a parallel artificial membrane permeability assay experiment (PAMPA) [1]. Cell Cytotoxicity Assay [1] Cell Line: SH-SY5Y, PC12, BV2 and HT-22 cells Concentration: 5-100 μM Incubation Time: 24 hours Result: Showed cells viability more than 60% of SH-SY5Y, PC-12 and HT-22 even at 100 μM. Showed high mortality in BV2 cells, and reached half the mortality at 20 μM.

BChE-IN-13 (oral gavage; 15 mg/kg; once daily; 6 d) shows the improvement in memory and cognitive function in Aβ 1-42 induced AD-like disorder mice [1]. Animal Model: ICR mice intracerebroventricularly (icv) injected with oligomerized Aβ 1-42 Dosage: 15 mg/kg Administration: Oral gavage; 15 mg/kg; once daily; 6 days Result: Improved the memory and cognitive function, and showed a shorter latency compared with Donepezil.